INDIVIOR PLC(INDV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INDV INDIVIOR PLC

Trading 04-21 11:29:57 EDT

32.66

+0.24

+0.74%

High32.73	Low32.28	Vol147.01K
Open32.46	D1 Closing32.42	Amplitude1.39%
Mkt Cap3.98B	Tradable Cap3.40B	Total Shares121.92M
T/O4.79M	T/O Rate0.14%	Tradable Shares104.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"INDV","market":"US","secType":"STK","nameCN":"INDIVIOR PLC","latestPrice":32.66,"timestamp":1776785391482,"preClose":32.42,"halted":0,"volume":147010,"delay":0,"changeRate":0.00740283775447239,"floatShares":104000000,"shares":121922058,"eps":0.981213,"marketStatus":"Trading","change":0.24,"latestTime":"04-21 11:29:57 EDT","open":32.46,"high":32.73,"low":32.28,"amount":4785127.7217500005,"amplitude":0.01388,"askPrice":32.69,"askSize":5,"bidPrice":32.6,"bidSize":648,"shortable":3,"etf":0,"ttmEps":0.981213,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1776801600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":32.42,"preHourTrading":{"tag":"盘前","latestPrice":32.26,"preClose":32.42,"latestTime":"09:04 EDT","volume":427,"amount":13788.52601,"timestamp":1776776677370,"change":-0.16,"changeRate":-0.004935,"amplitude":0.037335},"postHourTrading":{"tag":"盘后","latestPrice":32.42,"preClose":32.42,"latestTime":"19:43 EDT","volume":61283,"amount":1986662.65,"timestamp":1776728602578,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.39349,"impliedVol":0.582,"impliedVolPercentile":0.6135},"requestUrl":"/m/hq/s/INDV","defaultTab":"news","newsList":[{"id":"2628875051","title":"Does Indivior (INDV) Survey Support For Long-Acting Buprenorphine Strengthen Its Criminal Justice Strategy?","url":"https://stock-news.laohu8.com/highlight/detail?id=2628875051","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628875051?lang=en_us&edition=fundamental","pubTime":"2026-04-19 09:09","pubTimestamp":1776560990,"startTime":"0","endTime":"0","summary":"In April 2026, Indivior PLC reported results from a national survey showing that correctional leaders see staffing and coordination gaps as major barriers to preventing diversion of medications for opioid use disorder, and view long-acting injectable buprenorphine as a practical way to improve treatment in jails and prisons.\nThe survey’s strong support among correctional professionals for long-acting injectable buprenorphine highlights a potential opportunity for wider use of Indivior’s...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior-pharmaceuticals/news/does-indivior-indv-survey-support-for-long-acting-buprenorph","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior-pharmaceuticals/news/does-indivior-indv-survey-support-for-long-acting-buprenorph","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","INDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628243979","title":"Indivior survey finds 88% of jail staff back injectable buprenorphine to curb diversion","url":"https://stock-news.laohu8.com/highlight/detail?id=2628243979","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628243979?lang=en_us&edition=fundamental","pubTime":"2026-04-17 02:36","pubTimestamp":1776364618,"startTime":"0","endTime":"0","summary":"Indivior announced results from a national survey published in Journal of Correctional Health Care that assessed approaches to limit misuse of medications for opioid use disorder in US jails and prisons.Survey findings indicated correctional leaders view long-acting injectable buprenorphine as a way to curb medication diversion while supporting treatment delivery.Most respondents in both jail and prison settings reported that monthly injectable dosing could help reduce misuse inside facilities.Responses also pointed to staffing constraints and weak coordination between custody and health teams as major barriers to effective opioid treatment programs.Cost and access concerns were cited as key obstacles that could limit adoption despite perceived operational benefits.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260416:nNDL8tK8qQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626165124","title":"Could Indivior (INDV) Turn Correctional Staffing Efficiencies Into a Durable Competitive Edge?","url":"https://stock-news.laohu8.com/highlight/detail?id=2626165124","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626165124?lang=en_us&edition=fundamental","pubTime":"2026-04-10 11:38","pubTimestamp":1775792330,"startTime":"0","endTime":"0","summary":"Indivior Pharmaceuticals recently reported that a new cost impact model, published in The Journal of Current Medical Research and Opinion, found its monthly injectable SUBLOCADE® could significantly reduce staff time and related costs for treating opioid use disorder in U.S. jails and prisons versus other medication options.\nThe study’s suggestion that extended-release buprenorphine may ease operational burdens in correctional healthcare could influence policymakers and institutional buyers...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior-pharmaceuticals/news/could-indivior-indv-turn-correctional-staffing-efficiencies","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-indv/indivior-pharmaceuticals/news/could-indivior-indv-turn-correctional-staffing-efficiencies","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626186423","title":"Indivior to report Q1 financial results, host webcast update","url":"https://stock-news.laohu8.com/highlight/detail?id=2626186423","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626186423?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:03","pubTimestamp":1775732617,"startTime":"0","endTime":"0","summary":"Indivior schedules Q1 2026 financial results release for April 30, 2026 at 7:00 a.m. EDT.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL8gYV3x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","NDAQ","BK4588","SG9999014005.SGD","LU2095319765.USD","IE00BKPKM429.USD","SG9999014039.USD","LU2210149790.SGD","IE00BGHQF748.EUR","INDV","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK4585","BK4112","LU0314104364.USD","SG9999014021.USD","IE00B64PRP62.GBP","BK4007","SG9999014013.SGD","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626186150","title":"Press Release: Indivior to Report First Quarter 2026 Financial Results and Host Webcast on April 30th","url":"https://stock-news.laohu8.com/highlight/detail?id=2626186150","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626186150?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:00","pubTimestamp":1775732400,"startTime":"0","endTime":"0","summary":"RICHMOND, Va., April 09, 2026  -- Indivior Pharmaceuticals, Inc.  today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, at 7:00 a.m. U.S. EDT. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EDT.The webcast event and materials can be accessed on the \"Investors\" section of the company's website at www.indivior.com before the event begins.Participants may access the presentation telephonically by registering with the following link:. A replay of the presentation will be available at www.indivior.com.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4007","BK4181","HST","INDV","BK4218"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624564305","title":"Indivior model shows monthly Sublocade cuts jail MOUD staffing time versus methadone, oral buprenorphine","url":"https://stock-news.laohu8.com/highlight/detail?id=2624564305","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624564305?lang=en_us&edition=fundamental","pubTime":"2026-04-01 06:12","pubTimestamp":1774995136,"startTime":"0","endTime":"0","summary":"Indivior-backed cost impact model estimated monthly injectable buprenorphine  could cut staff time in jails and prisons versus methadone, oral buprenorphine, weekly extended-release buprenorphine, or extended-release naltrexone.Model projected 318 fewer staff hours per month per 100 patients versus methadone.Staffing requirement fell by 747 hours versus oral buprenorphine.Reduced staff time translated into monthly cost savings of up to USD 22,148, driven by less daily observed dosing and fewer patient escorts.Study flagged limits, including exclusion of drug acquisition costs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief on March 31, 2026, a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLbL1QlT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623970308","title":"REFILE-FOCUS-Drugmakers delay some European launches with a wary eye on Trump's pricing policies","url":"https://stock-news.laohu8.com/highlight/detail?id=2623970308","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623970308?lang=en_us&edition=fundamental","pubTime":"2026-03-31 14:00","pubTimestamp":1774936800,"startTime":"0","endTime":"0","summary":"REFILE-FOCUS-Drugmakers delay some European launches with a wary eye on Trump's pricing policiesCorrects typographical error in anti-inflammatory drug name Brinsupri in paragraph 15Trump most-favored-nation deals cause pricing uncertaintyData shows 35% drop in European new drug launchesCompanies say they want more clarity on US prices first Situation bolsters US position as first go-to marketEurope needs to rethink drug pricing to stay competitive, lobby group saysBy Maggie Fick, Bhanvi Satija and Dominique Patton","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nL4N40D163:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1301847155.USD","LU0211326839.USD","LU1989771016.USD","LU0047473722.EUR","LU0320765992.SGD","LU0047473722.SGD","LU0310800379.SGD","INDV","LU0266013472.USD","LU2089984988.USD","LU2089283258.USD","LU0972486137.USD","LU0868494617.USD","LU0496365809.HKD","LU1196032939.SGD","LU1880407132.USD","LU0545039389.USD","BK4566","AMGN","LU0211327993.USD","LU0949170426.SGD","BK4533","LU1989772923.USD","LU2125909593.SGD","LU0029864427.USD","LU1153585028.USD","LU2112291526.USD","LU0963555726.SGD","LU0345777659.USD","LU0960981461.USD","IE00B3T34201.USD","LU1153584641.USD","LU2242652126.USD","LU2293690082.USD","LU0077335932.USD","INSM","LU0889565080.SGD","LU1487256676.USD","LU1496350171.SGD","AZN.UK","LU2108987350.USD","LU0823416689.USD","LU1170363599.USD","LU0792757196.USD","LU1064927863.SGD","LU1983299246.USD","LU1291159041.SGD","SG9999001176.SGD","03165","SG9999001176.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622847221","title":"Indivior announces annual shareholder meeting; FY2025 total net revenue rises to $1.2 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2622847221","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622847221?lang=en_us&edition=fundamental","pubTime":"2026-03-27 18:07","pubTimestamp":1774606037,"startTime":"0","endTime":"0","summary":"Indivior will hold its annual meeting on May 13, 2026, via a virtual meeting platform.Shareholders will vote on the election of eight directors to one-year terms.An advisory vote will be held on named executive officer compensation.An advisory vote will be held on the preferred frequency of future executive compensation votes.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL4xXxXs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621770727","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2621770727","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621770727?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:34","pubTimestamp":1774265667,"startTime":"0","endTime":"0","summary":"Apogee Therapeutics  stock was up 18% pre-bell Monday after the company said that 52-week maintenance data from Part A of its phase two trial of zumilokibart in patients with moderate-to-severe atopic dermatitis demonstrated durable maintenance response and \"deepening\" response for lesional and itch endpoints.Indivior  shares were 13% higher following a 3.9% loss in the previous session.Synopsys  stock was up 4.2% after media reports over the weekend that Elliott Investment Management has built a multibillion-dollar stake in the company.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1861215975.USD","LU1861214812.USD","LU0053671581.USD","SGXZ51526630.SGD","BK4007","LU0957791311.USD","LU1815333072.USD","LU0082616367.USD","LU0096362180.USD","BK4139","LU1303367103.USD","SG9999004303.SGD","LU0444971666.USD","LU2125909593.SGD","LU1721428933.USD","LU1854103824.USD","LU2433249047.HKD","LU2290526834.HKD","LU1861219969.SGD","SGXZ99366536.SGD","APGE","BK4023","LU2413666426.HKD","LU1989764748.USD","LU0889565833.HKD","LU0061474960.USD","LU0347712357.USD","LU2360107168.USD","SNPX","IE00BZ199S13.USD","IE00BKPKM429.USD","LU0957808578.USD","LU1815336760.USD","LU2458330169.SGD","SNPS","LU2063271972.USD","BK4588","LU1923622291.USD","BK4585","BK4533","LU0109392836.USD","LU2247934214.USD","LU1951200564.SGD","LU1989764664.SGD","LU2125909247.SGD","LU1923622614.USD","LU1642822529.SGD","LU0719512351.SGD","INDV","LU0390134368.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620405838","title":"Indivior Issues $500 Million Convertible Senior Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2620405838","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620405838?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:42","pubTimestamp":1773780132,"startTime":"0","endTime":"0","summary":"An update from Indivior ( ($INDV) ) is now available. On March 17, 2026, Indivior Pharmaceuticals, Inc. issued $500 million of 0.625% Convertible S...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/indivior-issues-500-million-convertible-senior-notes-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/indivior-issues-500-million-convertible-senior-notes-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620609408","title":"Indivior Pharmaceuticals issues USD 500 million 0.625% convertible senior notes due 2031","url":"https://stock-news.laohu8.com/highlight/detail?id=2620609408","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620609408?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:08","pubTimestamp":1773778093,"startTime":"0","endTime":"0","summary":"Indivior issued USD 500 million of 0.625% convertible senior notes due 2031 under an indenture with U.S. Bank Trust Company. The company used part of the proceeds to prepay all amounts outstanding under a note purchase agreement with RBP Global Holdings, Indivior Global Holdings, Piper Sandler Finance, and lender parties, and terminated that agreement. The notes pay interest semi-annually and mature on March 15, 2031.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL4SfFbT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","INDV","BK4559","BK4585","BK4127","LU1894683348.USD","PIPR","LU1894683264.USD","LU2237438978.USD","USB","BK4504","LU0053671581.USD","LU0170899867.USD","BK4007","BK4588","LU1883839398.USD","BK4207"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620479967","title":"Indivior-backed survey finds 58% of U.S. correctional facilities offer at least one FDA-approved MOUD","url":"https://stock-news.laohu8.com/highlight/detail?id=2620479967","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620479967?lang=en_us&edition=fundamental","pubTime":"2026-03-18 00:02","pubTimestamp":1773763369,"startTime":"0","endTime":"0","summary":"Indivior reported results from a cross-sectional survey published in the Journal of Correctional Health Care assessing access to medications for opioid use disorder  in U.S. correctional facilities. The study, conducted with the National Commission on Correctional Health Care, surveyed 212 jails, prisons, and detention centers and found that 58% offered at least one FDA-approved MOUD. The survey found that jails were more than twice as likely as prisons to provide MOUD, and facilities in the West had more than triple the odds of offering MOUD compared with those in the Midwest. Respondents cited implementation barriers including stigma, abstinence-only approaches, limited provider training, and constrained budgets. Qualitative feedback highlighted needs for reentry support such as housing, care coordination, and expanded use of long-acting injectables and telehealth.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL29JcsT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDV","SG9999014021.USD","BK4588","IE00BKPKM429.USD","LU0314104364.USD","SG9999014013.SGD","LU2095319765.USD","BK4585","IE00BN0W2T93.GBP","IE00BGHQF748.EUR","BK4007","LU2210149790.SGD","SG9999014005.SGD","NDAQ","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","BK4112","SG9999014039.USD","LU2210150020.SGD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619887148","title":"Indivior Pharmaceuticals Director Barbara Ryan Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2619887148","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619887148?lang=en_us&edition=fundamental","pubTime":"2026-03-14 04:26","pubTimestamp":1773433580,"startTime":"0","endTime":"0","summary":"Barbara Ryan, a director of Indivior Pharmaceuticals Inc., reported an acquisition of common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nNDL5Mz5H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Indivior Pharmaceuticals Director Barbara Ryan Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619114727","title":"BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2619114727","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619114727?lang=en_us&edition=fundamental","pubTime":"2026-03-14 01:54","pubTimestamp":1773424469,"startTime":"0","endTime":"0","summary":"BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen BioWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL6N4010OX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CCUP","CMCT","CVNY","SANA","VACH","HBAN","IBG","ESQ","KLAR","AMAT","KLC","RJF","CRCO","ICRC","ADBG","KYIV","ISPC","BIAF","AMPY","CRCD","AIFF","TVGN","INMD","PAR","IMM.AU","CRCA","SDHC","INDV","LVWR","CVNX","ULTA","ARES","VEON","FITB","WDCX","DOUG","CVNA","CRVS","PODD","SVCO","OFRM","BW"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2619411877","title":"BUZZ-Indivior Pharma rebounds after upsized $450 mln convertible bond offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2619411877","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619411877?lang=en_us&edition=fundamental","pubTime":"2026-03-13 22:01","pubTimestamp":1773410508,"startTime":"0","endTime":"0","summary":"BUZZ-Indivior Pharma rebounds after upsized $450 mln convertible bond offering** Indivior Pharmaceuticals INDV.O shares gap up as much as 4.3% to $32.18 early Fri after above-target haul** North Chesterfield, VA-based opioid use disorder treatment firm late Thurs announced pricing private offering of $450 mln 0.625% 5-yr convertible bonds ** Initial conversion price of $41.66 is 35% premium over stock's last close** INDV shares finished down 6% on Thurs after co announced $400 mln offering** Co intends to use ~$239 mln of net offering proceeds along with $102 mln of cash on hand to repay borrowings under term loan and revolver** It also plans to repurchase about 2.4 mln shares, ~$75 mln worth, to facilitate hedging by investors in the CBs** Stock last up 2.9% at $31.74. Shares down ~12% YTD after 189% gain in 2025** All 7 analysts are bullish including 2 \"strong buy\" ratings; median PT $48, per LSEG data","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL6N4010Y7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","INDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619598601","title":"Indivior Prices Upsized $450.0 Million Convertible Senior Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2619598601","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619598601?lang=en_us&edition=fundamental","pubTime":"2026-03-13 08:30","pubTimestamp":1773361800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nTUA4SNRXP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","INDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618131529","title":"Indivior Pharmaceuticals Plans $400 Million Private Debt Offering; Shares Down Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2618131529","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618131529?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:50","pubTimestamp":1773316221,"startTime":"0","endTime":"0","summary":"Indivior Pharmaceuticals  said Thursday it plans a $400 million private offering of convertible senior unsecured notes due March 15, 2031.The company expects to grant the initial purchasers a 30-day option to buy up to an additional $60 million of the notes.Indivior said it plans to use the net proceeds to help repay borrowings under and terminate the note purchase agreement that governs its term loan and revolving credit facility, among other things.The company's shares were down 5.3% in premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","INDV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618713138","title":"Indivior announces proposed convertible senior notes offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2618713138","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618713138?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:37","pubTimestamp":1773315451,"startTime":"0","endTime":"0","summary":"Indivior (INDV) Pharmaceuticals announced its intention to offer, subject to market and other conditions, $400,000,000 aggregate principal amount o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/indivior-announces-proposed-convertible-senior-notes-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/indivior-announces-proposed-convertible-senior-notes-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618013661","title":"Indivior plans USD 400 million convertible senior notes offering due 2031","url":"https://stock-news.laohu8.com/highlight/detail?id=2618013661","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618013661?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:03","pubTimestamp":1773313391,"startTime":"0","endTime":"0","summary":"Indivior announced a proposed private offering of USD 400 million of convertible senior notes due 2031, with an option for initial purchasers to buy up to an additional USD 60 million. If fully exercised, the total issuance would be USD 460 million. Indivior said it plans to use about USD 239 million of net proceeds plus about USD 102 million of cash on hand to repay borrowings and terminate its term loan and revolving credit facility agreement. The company also expects to use up to about USD 75 million of net proceeds to repurchase common shares from certain note purchasers in concurrent private transactions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nNDLPxSC5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4588","BK4585","SG9999014013.SGD","BK4007","SG9999014021.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2095319765.USD","LU0314104364.USD","INDV","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ","SG9999014039.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618135721","title":"Indivior Pharmaceuticals, Inc - to Use $239 Mln Net Proceeds and $102 Mln Cash to Repay Borrowings","url":"https://stock-news.laohu8.com/highlight/detail?id=2618135721","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618135721?lang=en_us&edition=fundamental","pubTime":"2026-03-12 19:00","pubTimestamp":1773313203,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nTUACDVGS0:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INDV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.indivior.com","stockEarnings":[{"period":"1week","weight":0.0259},{"period":"1month","weight":0.1065},{"period":"3month","weight":-0.0161},{"period":"6month","weight":0.302},{"period":"1year","weight":2.5982},{"period":"ytd","weight":-0.0964}],"compareEarnings":[{"period":"1week","weight":0.033},{"period":"1month","weight":0.0927},{"period":"3month","weight":0.046},{"period":"6month","weight":0.0613},{"period":"1year","weight":0.3463},{"period":"ytd","weight":0.0393}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in approximately 40 countries worldwide. It has collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.","yearOnYearQuotes":[{"month":1,"riseRate":0.583333,"avgChangeRate":0.021864},{"month":2,"riseRate":0.583333,"avgChangeRate":0.011788},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.007447},{"month":4,"riseRate":0.833333,"avgChangeRate":0.025883},{"month":5,"riseRate":0.909091,"avgChangeRate":0.072883},{"month":6,"riseRate":0.454545,"avgChangeRate":0.053237},{"month":7,"riseRate":0.8,"avgChangeRate":0.171847},{"month":8,"riseRate":0.545455,"avgChangeRate":-0.014379},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.095405},{"month":10,"riseRate":0.363636,"avgChangeRate":0.007009},{"month":11,"riseRate":0.545455,"avgChangeRate":0.010295},{"month":12,"riseRate":0.636364,"avgChangeRate":0.020229}],"exchange":"NASDAQ","name":"INDIVIOR PLC","nameEN":"INDIVIOR PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"INDIVIOR PLC(INDV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest INDIVIOR PLC(INDV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"INDIVIOR PLC,INDV,INDIVIOR PLC股票,INDIVIOR PLC股票老虎,INDIVIOR PLC股票老虎国际,INDIVIOR PLC行情,INDIVIOR PLC股票行情,INDIVIOR PLC股价,INDIVIOR PLC股市,INDIVIOR PLC股票价格,INDIVIOR PLC股票交易,INDIVIOR PLC股票购买,INDIVIOR PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"INDIVIOR PLC(INDV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest INDIVIOR PLC(INDV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction